The objectives of this study were to examine and identify differences in breast cancer-specific mortality risk factors of interest among patients with EBC in the Surveillance, Epidemiology, and End Results (SEER) registry, by HR, HER2 subtype, and to evaluate the relative contribution of those clinical and pathologic characteristics of interest to breast cancer-specific mortality by subtype. This evidence concerns the gene ERBB2 and breast cancer.